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Background: The proposed involvement of CD151 in breast cancer (BCa) progression is based on findings from studies in invasive
ductal carcinoma (IDC). The IDC and invasive lobular carcinoma (ILC) represent distinct disease entities. Here we evaluated clinical
significance of CD151 alone and in association with integrin a3b1 in patients with ILC in context of the data of our recent IDC study.
Methods: Expression of CD151 and/or integrin a3b1 was evaluated in ILC samples (N¼ 117) using immunohistochemistry. The
findings were analysed in relation to our results from an IDC cohort (N¼ 182) demonstrating a prognostic value of an expression of
CD151/integrin a3b1 complex in patients with HER2-negative tumours.
Results: Unlike in the IDCs, neither CD151 nor CD151/a3b1 complex showed any correlation with any of the ILC characteristics.
Lack of both CD151 and a3b1 was significantly correlated with poor survival (P¼ 0.034) in lymph node-negative ILC N( ) cases.
The CD151 /a3b1 patients had 3.12-fold higher risk of death from BCa in comparison with the rest of the ILC N( ) patients.
Conclusions: Biological role of CD151/a3b1 varies between ILC and IDC. Assessment of CD151/a3b1 might help to identify ILC
N( ) patients with increased risk of distant metastases.
The tetraspanin protein CD151 (Tspan24) has recently emerged as
a new candidate indicator of tumour cell invasiveness (Boucheix
and Rubinstein, 2001; Hemler, 2005; Zoller, 2009). Elevated
expression of CD151 protein and its involvement in tumour
progression have been observed in various human malignancies
(Romanska and Berditchevski, 2011). In breast cancer (BCa), in
particular, high expression of tetraspanin CD151 was shown to
correlate with axillary lymph node involvement and patient poor
overall survival (Sadej et al, 2009; Kwon et al, 2012; Novitskaya
et al, 2014). The role of CD151 in tumour invasive and metastatic
progression is thought to be relying on its ability to form
complexes with laminin-binding integrin receptors (i.e., a6b1,
a3b1, a6b4) (Sadej et al, 2014) and its involvement in the regulation
of cell–cell and cell–matrix interactions (Johnson et al, 2009).
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The underlying signalling pathways are likely to depend on
adhesion-dependent and coordinated activation of small Rho and
Ras GTPases, c-Akt and p38 (Novitskaya et al, 2014). It was also
proposed that the CD151/a3b1 complex is directly linked to
cadherin and catenin, thus regulating E-cadherin-mediated
cell–cell adhesion (Chattopadhyay et al, 2003). A suppressive role
of the CD151/a3b1 complex, recently demonstrated in ovarian
cancer, has been linked to stabilisation of integrin a3b1- and
E-cadherin-mediated cell–cell contacts (Baldwin et al, 2014). In
addition to its role in regulation of adhesion-dependent outside-in
signalling pathways, CD151 might contribute to mammary
tumourigenesis via ErbB2/HER2 (Deng et al, 2012; Novitskaya
et al, 2014). Interestingly, clinical analyses of BCa patients showed
that the elevated expression of CD151 correlated with poor overall
survival in patients only with HER2-negative (luminal A and
quintuple-negative) tumours (Kwon et al, 2012). Moreover, an
impact of CD151/a3b1 on invasive ductal carcinoma (IDC) patient
survival was shown to be inversely correlated with the level of
HER2 expression (Novitskaya et al, 2014).
Existing knowledge of CD151 involvement in mammary
tumourigenesis is almost exclusively based on clinical and
in vitro studies of the IDC. However, it is becoming increasingly
apparent that CD151 might have diverse, even opposing roles, in
different biological contexts and its clinical significance should be
investigated in relation to the phenotypical and histological
variants of the tumour (Voss et al, 2011).
Invasive lobular carcinoma (ILC) accounts forB10% to 15% of
newly diagnosed breast carcinomas. Classical ILCs are charac-
terised by an outgrowth of small, uniform discohesive neoplastic
cells that invade the stroma in a single-file pattern (Sikora et al,
2014). The majority of ILC tumours are of low histological grade
and preferentially display a luminal A phenotype (ERþ /PRþ /
HER2 ) (Weigelt et al, 2010). Classical ILCs lack E-cadherin
expression that is considered a defining feature of this BCa type
(Sikora et al, 2014). Recent studies demonstrated that ILCs differ
from grade- and molecular subtype-matched IDCs in the
transcriptomic profiles related to cell adhesion, cell–cell signalling
and metastatic pattern, indicating that IDCs and ILCs represent
distinct disease entities (Weigelt et al, 2010; Sikora et al, 2014).
Because of the relatively low incidence of ILC as well as the
paucity of available research models (Sikora et al, 2014), the
mechanisms underlying its pathophysiology are poorly under-
stood. It is likely that the role of CD151 in progression of
E-cadherin-inactivated ILCs, and hence its impact on patient
outcome, differs from those documented in the more common
IDCs. To date, CD151 expression has been studied only in a few
ILC cases, a small part (2.9%; 25 out of 886) of a large cohort
analysed according to the phenotypical and not the histological
subtypes (Kwon et al, 2012). More information is available
regarding expression of integrins in ILC. Most reports are in
agreement that malignant ILC phenotype is associated with
decrease of expression of a range of integrin subunits. However,
independently, the integrins seem to be of limited clinical value as
no correlation between their expression, histological grade, nodal
involvement, proliferative activity or, above all, the overall survival
has ever been found (Gui et al, 1995; Lanzafame et al, 1996;
Gonzalez et al, 1999; Gonzalez-Angulo et al, 2006).
The a3b1 integrin forms a stoichiometric complex with
the tetraspanin CD151 and the interaction with CD151 is
functionally important in a3 integrin-dependent matrix remodel-
ling and cell spreading (Kazarov et al, 2002). The aim of our study
was to assess clinical significance of CD151 alone and in
association with integrin a3b1 in a group of patients with ILC.
The findings were analysed in context of our recent IDC study
demonstrating a prognostic value of an expression of integrin
CD151/a3b1 complex in patients with HER2-negative tumours
(Novitskaya et al, 2014).
MATERIALS AND METHODS
Patient selection and samples. The study included radical surgery
specimens of primary ILC from 117 patients treated between 2000
and 2008 at three sites: (1) the Oncology Department of
Copernicus Memorial Hospital in Ło´dz´, Poland, (2) the UHB
NHSFT, Birmingham, UK and (3) the Leeds Teaching Hospitals
NHS Trust, Leeds, UK. All samples were obtained according to the
local ethical regulations (project ethics licence: RNN/174/11/KE).
The characteristics of the study population are summarised in
Table 1. Follow-up period was defined as the time from surgery to
the last observation for censored cases or death for complete
observations.
Immunohistochemistry. Serial 5 mm paraffin sections of forma-
lin-fixed blocks were processed for immunohistochemistry for
CD151 (mouse anti-human; 1 : 100; Novocastra, Newcastle upon
Tyne, UK) and a3b1 (INTA3) (goat anti-human; 1 : 200, Santa
Cruz, Wembley, UK) using protocols described previously
(Novitskaya et al, 2014). Immunostaining for E-cadherin (mouse
anti-human, 1 : 50; Novocastra) was used to confirm the initial
pathological diagnosis of ILC (E-cadherin-positive samples
were excluded from the study). As a negative control for
the immunostaining, primary antibodies were replaced by non-
immune sera.
Scoring of immunostaining for CD151 was based on Hofmann’s
method for membranous reactivity of ErbB2 (Hofmann et al, 2008)
and modified as follows: (1) 0/negative: no reactivity or only
partially membranous reactivity inp10% of tumour cells; (2) 1þ /
negative: faint membranous or partially membranous in X10% of
tumour cells; (3) 2þ /positive: weak to moderate complete
membranous in X10% of tumour cells; and (4) 3þ /positive:
strong complete membranous in X10% of the tumour cells.
Immunoreactivity for a3b1 was scored as follows: (1) 0/negative:
Table 1. Patient characteristics
Feature ILC IDC
Number of patients 117 182
Age (years)
o50 21 56
X50 96 127
Disease stagea
I 34 44
II 60 93
III 13 45
T statusb
T1 52 61
T2 48 112
T3 15 1
T4 1 8
Gradec
1 21 105
2–3 94 77
Nodal statusd
Negative 64 92
Positive 44 90
Steroid receptor statuse
Negative 11 79
Positive 102 103
HER2 statusf
Negative 102 151
Positive 4 31
Abbreviations: IDC¼ invasive ductal carcinoma; ILC¼ invasive lobular carcinoma. In the ILC
group, data are available for a107 patients, b116 patients, c115 patients, d108 patients, e113
patients and f106 patients.
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no reactivity; (2) 1þ /positive: faint membranous and/or cyto-
plasmic staining in X10% of tumour cells; (3) 2þ /positive: weak
to moderate membranous and/or cytoplasmic staining inX10% of
tumour cells; and (4) 3þ /positive: strong membranous and/or
cytoplasmic staining in X10% of the tumour cells. Immunohis-
tochemical staining was evaluated and scored independently by
two observers (HMR and R Kordek or HMR and SC). The
agreement on staining intensity was 490%. Where there was
disagreement, intensity was determined by consensus. Dichotomi-
sation of the final scores into: (1) ‘negative’ and (2) ‘positive’ for
CD151/0–2; INTA3/0 and CD151/3 and INTA3/1–3, respectively,
was guided by intensity of immunostaining in positive controls
recommended by the manufacturer.
Statistical analysis. Overall survival was calculated from the date
of surgery to the date of death or the last follow-up, as
recommended by the Kaplan–Meier method. Differences in
survival distributions were compared using log-rank test. Data
for patients who died from other causes than BCa were censored at
the time of death. Univariate analysis of overall survival was
performed using the Cox proportional hazards regression model.
Parameters showing a significant correlation (Po0.05) were
included in the multivariate logistic regression analysis. Pearson’s
w2 test or Fisher’s exact test were used to assess the associations
between expression of CD151 and a3b1 alone and their
coexpression and clinicopathological variables. The results were
considered statistically significant when two-sided P-value was
o0.05. The analyses were performed using the Statistica 9.1 and
Statistica 10 (StatSoft Inc., Tulsa, OK, USA) softwares.
Data on cancer recurrence were available in only four cases that
precluded the DFS analysis.
RESULTS
An impact of CD151/a3b1 on tumour biology differs between
ILC and IDC. In normal gland, both CD151 and a3b1 showed
moderate to strong, predominantly membranous immunoreactiv-
ity, confined to the basal and lateral surfaces of the myoepithelial
cells, with no or very weak staining in luminal epithelial cells
(Figure 1A). Similarly, in ILCs, CD151 and a3b1 were localised
mainly to the membrane of tumour cells and there was
a significant correlation (P¼ 0.012) between levels of their
expression (Table 2A). We observed four distinct patterns of
immunoreactivity for CD151/a3b1: (1) CD151þ /a3b1þ in 55
out of 117 (23.94%) cases; (2) CD151þ /a3b1 in 28 out of 117
(23.94%) cases; (3) CD151 /a3b1 in 20 out of 117 (17.09%)
cases and (4) CD151 /a3b1þ in 14 out of 117 (11.96%) cases
(Figure 1B–E). Interestingly, the level of CD151 expression (but
not expression of a3b1) on cancer cells was similar to that observed
on endothelial cells of intratumoural vessels (Figure 2).
There was no significant correlation between the level of a3b1
expression and any of tumour characteristics (Table 2A). On the
other hand, expression of CD151 assessed alone was inversely
associated with tumour size (P¼ 0.047) and stage (P¼ 0.019), thus
indicating that CD151 might have an ability to suppress
proliferation of cells and progression of disease. Interestingly,
positivity for both CD151 and a3b1 (CD151þ /a3b1þ ) was
significantly associated only with grade (P¼ 0.019). These results
suggest that phenotypic dedifferentiation and adopting of anaplas-
tic features by epithelial cells in ILC are associated with CD151
acting in a complex with a3b1.
We have previously reported that in IDC, in contrast to ILC,
CD151 expression showed a positive association with stage
(P¼ 0.030) and inverse with tumour grade (P¼ 0.041). We have
also demonstrated that, when assessed in combination, positivity
for CD151 and/or a3b1 correlated closer than CD151 alone with
stage of disease (Po0.001 vs P¼ 0.03 for CD151/a3b1 vs CD151,
respectively) (Novitskaya et al, 2014). Here we have expanded our
previous analyses and evaluated coexpression of CD151 and a3b1
in the context of histopathological and clinical characteristics of the
IDC cohort. The results showed that in contrast to ILCs, combined
positivity for both CD151 and a3b1 showed no correlation with
any of the clinicopathological features in IDCs (Table 2B). Taken
together, these results suggest that the involvement of CD151 and
its principal transmembrane partner, the integrin a3b1, in tumour
development and progression is likely to differ between histological
subtypes of BCa.
In ILC, in contrast to IDC, neither CD151 nor a3b1 hold
prognostic value. Neither CD151 nor a3b1 analysed alone were of
any prognostic value in ILCs (Table 3A). In contrast, in IDC, as
shown previously, CD151-positive patients had 1.88-fold higher
risk of death from BCa in comparison with CD151-negative
CD151 31
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Figure 1. Expression of CD151 and a3b1 in (A) normal gland (100;
insets  400). Both CD151 and a3b1 show moderate to strong,
predominantly membranous immunoreactivity, confined to the basal
and lateral surfaces of the myoepithelial cells, with no or very weak
staining in luminal epithelial cells. (B) The ILC cells of similar areas of
the tumour display various levels of CD151/a3b1 immunoreactivity
representing four predominant phenotypes: (B) CD151þ /a3b1þ
(55 out of 117; 49.01%); (C) CD151þ /a3b1 (28 out of 117; 23.94%)
(D) CD151 /a3b1 (20 out of 117; 17.09%) and (E) CD151 /a3b1þ
(14 out of 117; 11.96%).
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patients. Moreover, a multivariate statistical analysis identified
CD151 as an independent marker (P¼ 0.0172) of poor prognosis
in IDC (Table 4). In neither ILC nor IDC, coexpression was
significantly associated with patient survival. Furthermore,
although in the IDC cohort, clinicopathological characteristics
commonly recognised as independent prognostic factors (tumour
size, lymph node status, stage) were significantly associated with
poor survival, none of them held any prognostic value in our ILC
study population (Table 3A and B).
Lack of CD151/a3b1 expression is associated with poor survival
in node-negative ILC. As CD151, acting in partnership with
a3b1, is thought to affect invasive spread of tumour cells, we
analysed prognostic values of CD151 and/or a3b1 in the ILC
cohort in relation to the lymph node status. The results presented
in Table 5 demonstrate that neither CD151 nor a3b1 assessed
alone or in combination had any significant prognostic value in
any of the subgroups. Only a trend towards statistical significance
(P¼ 0.082) was seen for CD151 in node-negative patients (ILC
N( )). Furthermore, in the ILC N( ) subgroup, the data were
suggestive that the presence of either CD151 or a3b1 could be
favourable to the prognosis but their coexpression had no additive
effect on patient survival. Thus, we next looked at the relationships
between CD151 and/or a3b1 and tumour characteristics in the
lymph node-negative subgroup (characteristics of the group are
summarised in Table 6A). Table 6B demonstrates that, as in the
whole group, significant correlations between (1) expression of
CD151 and a3b1 (P¼ 0.018); (2) CD151 and tumour size
(P¼ 0.035); and (3) CD151/a3b1 and grade (P¼ 0.029) were
maintained. Univariate analysis in ILC N( ) cases showed that
lack of combined expression of CD151 and a3b1 was significantly
correlated with poor patient survival (P¼ 0.034) and was the only
prognostic factor in this group (Table 6C). The CD151/a3b1
negative patients had 3.12-fold higher risk of death from BCa in
comparison with the rest of the patients with no lymph node
involvement and the 5-year estimated survival rates were 64% vs
91%, respectively (Figure 3).
DISCUSSION
An overexpression of CD151/Tspan24 has been repeatedly
reported as a negative predictor of overall survival in patients
with invasive ductal breast carcinoma (Yang et al, 2008; Sadej et al,
2009; Kwon et al, 2012; Novitskaya et al, 2014) but nothing is
known about its clinical significance in invasive lobular BCa. Here
we demonstrate that, in contrast to IDC, loss of CD151 expression
in complex with that of its principal molecular partner, the integrin
a3b1, is significantly associated with poor survival in patients with
lymph node-negative ILC. There have been a few attempts to
establish an expression signature of a risk of distant metastasis in
primary lymph node-negative IDC (Mirza et al, 2002; Wang et al,
2007; Tutt et al, 2008). To the best of our knowledge, this is the
first study providing information on prognostic factors in a
subgroup of lymph node-negative ILC patients.
The results of our study provide support for the notion
of biological diversity of CD151 in human cancer. Acting alone
and/or in complex with laminin-binding integrins, CD151 has
been linked with various aspects of carcinogenesis (Palmer et al,
2014; Sadej et al, 2014). Although its pro-migratory and pro-
invasive functions are well established, it was also reported that in
certain cell types the presence of CD151 is associated with
suppression of motility. For example, its downregulation induced
by hypoxic stress at the primary site in colon cancer was shown to
Table 2. Association between CD151 and/a3b1 expression and clinicopathological features
(A)
P-value
ILC
Feature a3b1 (high: n¼69) CD151 (high: n¼83) CD151/a3b1 (high: n¼55)
a3 0.012
CD151 0.012
Size 0.574 0.047 0.381
Nodes 0.464 0.277 0.101
Stage 0.656 0.019 0.387
Grade 0.093 0.343 0.019
ErbB2 0.092 0.881 0.249
ER/PR 0.694 0.471 0.425
(B)
P-value
IDC
Feature a3b1 (high: n¼32) CD151 (high: n¼87) CD151 /a3b1 (high: n¼26)
a3b1 o0.001
CD151 o0.001
Size 0.599 0.497 0.499
Nodes 0.271 0.076 0.413
Stage 0.545 0.030 0.174
Grade 0.163 0.041 0.162
ErbB2 40.999 0.015 0.995
ER/PR 0.663 0.819 0.797
Abbreviations: ER/PR¼oestrogen receptor/progesterone receptor; IDC¼ invasive ductal carcinoma; ILC¼ invasive lobular carcinoma. The bold values are statistically significant.
CD151/a3b1 in lobular breast carcinoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.344 1353
decrease adhesion of cells to the extracellular matrix and enhance
cell motility (Chien et al, 2008). Similarly, both up- and
downregulation of integrin a3b1 expression have been correlated
with tumour invasion and poor prognosis (Adachi et al, 1998;
Fukushima et al, 1998; Gustafson-Wagner and Stipp, 2013).
Furthermore, the CD151/a3b1 complex has been recently shown
to suppress ovarian tumour growth (Baldwin et al, 2014). Although
in our study no prognostic value could be ascribed to either CD151
or a3b1 assessed alone, their independent suppressor-like
functions cannot be excluded. Further mechanistic investigation
would be required to evaluate an actual impact of a loss of the
CD151/a3b1 complex on ILC tumour behaviour.
Increasing evidence suggests that ILCs and IDCs are biologically
different. This is reflected in disparities in morphological and
phenotypic characteristics, transcriptomic profiles related particu-
larly to cell–cell and cell–matrix interactions (Weigelt et al, 2010),
as well as responsiveness to neoadjuvant therapy (Korkola et al,
2003). As demonstrated by several genomic studies, the only
consistent finding characterising ILC tumours is inactivation of
CDH1 (E-cadherin, cadherin-1) (Bertucci et al, 2008; Weigelt et al,
2008, 2010; Sikora et al, 2013) and, indeed, lack of E-cadherin
expression is considered a hallmark of ILC. Although the role of
E-cadherin in tumour onset and progression is still largely
unknown, its inactivation alone is clearly not sufficient to induce
CD151
A
B
C
*
*
*
*
Figure 2. Expression of CD151 in intratumoural vessels ( 400). Level
of expression in endothelial cells of intratumoural vessels (asterisks) is
consistent with that in epithelial cells of adjacent tumour (arrows)
(A, high; B, moderate; C, negative).
Table 3. Univariate analysis of prognostic factors
(A)
Factor HR 95% CI P-value
ILC
a3b1 0.80 0.39–1.61 0.750
CD151 0.56 0.28–1.14 0.109
CD151/a3b1 0.72 0.35–1.49 0.380
(T1 vs T2–4) 1.78 0.84–3.78 0.165
Nodal status 1.61 0.78–3.31 0.195
Stage (I vs II vs III) 2.08 0.85–5.11 0.111
ER/PR 0.46 0.17–1.19 0.110
HER2 NAa NAa NAa
Grade (G1–2 vs G3) 1.46 0.55–3.87 0.441
(B)
IDC
a3b1 1.10 0.60–2.03 0.750
CD151 1.88 1.15–3.08 0.012
CD151/a3b1 0.98 0.48–1.98 0.952
(T1 vs T2–4) 1.77 1.30–2.40 o0.001
Nodal status 3.01 1.78–5.10 o0.001
Stage (I vs II vs III) 1.81 1.27–2.57 o0.001
ER/PR 0.53 0.33–0.87 0.011
HER2 2.07 1.18–3.64 0.012
Grade (G1–2 vs G3) 1.24 0.76–2.01 0.383
Abbreviations: CI¼ confidence interval; ER/PR¼oestrogen receptor/progesterone recep-
tor; HR¼ hazards ratio; IDC¼ invasive ductal carcinoma; ILC¼ invasive lobular carcinoma;
NA¼ not analysed.
aOnly 4 were HER2 positive. The bold values are statistically significant.
Table 4. Multivariate analysis of prognostic factors
IDC
Factor HR 95% CI P value
CD151 1.92 1.12–3.31 0.0172
(T1 vs T2-4) 1.98 0.94–4.15 0.0711
Nodal status 4.11 2.04–8.29 o0.0001
Stage (I vs II vs III) 0.68 0.38–1.23 0.2063
ER/PR 0.53 0.32–0.91 0.0198
HER2 1.20 0.71–2.04 0.1927
Abbreviations: CI¼ confidence interval; ER/PR¼oestrogen receptor/progesterone receptor;
HR¼ hazards ratio; IDC¼ invasive ductal carcinoma. The bold values are statistically significant.
Table 5. Univariate analysis of prognostic value of CD151
and/or a3b1 in relation to lymph node status
ILC N(þ ) ILC N( )
Factor HR 95% CI P-value HR 95% CI P-value
a3b1 1.28 0.45–3.60 0.641 0.46 0.16–1.31 0.146
CD151 0.64 0.22–1.87 0.412 0.40 0.14–1.22 0.082
CD151/a3b1 1.02 0.35–3.00 0.970 0.72 0.35–1.49 0.187
Abbreviations: CI¼ confidence interval; HR¼ hazards ratio; ILC¼ invasive lobular
carcinoma.
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neoplastic growth. It has been shown that combined loss of
E-cadherin and p53, but not E-cadherin alone, in murine
mammary epithelial cells induces metastatic carcinomas that
resemble human ILC (Derksen et al, 2006).
There are several reports suggesting that an association of
CD151 with integrin a3b1 might be important for regulation of
E-cadherin-dependent cell–cell interactions. In mouse kidney, the
CD151/integrin a3b1, acting as both an organiser and a component
of a large multimolecular complex containing E-cadherin–b-catenin,
promoted its association with the actin cytoskeleton and cadherin-
mediated cell–cell adhesion. Deletion of integrin a3b1 in this system
was found to disturb E-cadherin localisation and function
(Chattopadhyay et al, 2003). In highly expressing E-cadherin human
keratinocytes (HaCat cell line), blocking of CD151 supported cell
dispersal (Chometon et al, 2006), whereas CD151 overexpression
enhanced carcinoma cell–cell association (Shigeta et al, 2003).
Similarly, in A431 epithelial carcinoma cells, near total silencing of
CD151 destabilised E-cadherin-dependent cell–cell junctions. How-
ever, it was not the disruption of the E-cadherin regulatory complex
but an excessive RhoA activation and disorganisation of actin fibres at
the cell–cell junctions, induced by loss of CD151, that led to the
enhancement of cell migration (Johnson et al, 2009). Through
stabilisation of E-cadherin based cell–cell interactions, CD151 was
suggested to counteract the metastatic progression of endometrial
cancer (Voss et al, 2011). Activation of Rho/ROCK signalling axis
triggered by loss of E-cadherin was recently demonstrated to be
responsible for induction of anoikis resistance and invasive phenotype
in a mouse model of human ILC (Schackmann et al, 2011).
Interestingly, results of our own study have shown that in IDC cells,
depletion of CD151 and a3b1 caused increase of active RhoA
(Novitskaya et al, 2014). Taken together, these findings seem to
suggest that although loss of E-cadherin is a prerequisite of the lobular
phenotype, other factors, including, perhaps, the CD151-a3b1
partnership, also contribute to invasive behaviour of cancer cells.
The results of our study demonstrated that unlike IDC, lack of
both CD151 and integrin a3b1 correlated with decreased survival of
patients with lymph node-negative ILCs. Unlike IDC, ILC tumour
cells are deprived of E-cadherin expression and the function and
significance of the CD151/a3b1 complex in biology of E-cadherin-
negative cells are poorly characterised. However, it is conceivable that
in this particular biological context, as in the settings described above,
the CD151/a3b1 complex is controlling cell–cell adhesion and loss of
E-cadherin contributes but is not decisive in destabilisation of cell–
cell contacts and enhancement of cell migration.
The pathogenesis of IDC and ILC seems indeed to be governed
by distinct mechanisms. Not only the high expression of CD151,
but also the lymph node status, one of the most clinically
important indicators of poor prognosis in IDC, was not correlated
Table 6A. Lymph node-negative subgroup. Patient
characteristics
Feature ILC
Number of patients 64
Age (years)
o50 10
X50 54
Disease stagea
I 34
II 28
III 1
T statusa
T1 34
T2–T4 29
Gradeb
1 13
2–3 49
Steroid receptor statusc
Negative 5
Positive 58
HER2 status
Negative 64
Abbreviation: ILC¼ invasive lobular carcinoma. Data available for a63 patients, b62 patients
and c63 patients.
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Figure 3. Kaplan–Meier curves of overall survival for patients with
invasive lobular breast cancer. Overall survival of patients with tumours
negative for both CD151 and a3b1 in relation to the rest of the
cohort.
6B. Association of CD151 and/or a3b1 and tumour
characteristics
a3b1
(high: n¼38)
CD151
(high: n¼47)
CD151/a3b1
(high: n¼32)
a3b1 0.018
CD151 0.018
Tumour size (T1 vs T2–4) 0.312 0.035 0.892
Grade 0.079 0.342 0.029
HER2 NAa NAa NAa
ER 0.377 0.999 0.192
PR NAb NAb NAb
Abbreviations: ER/PR¼oestrogen receptor/progesterone receptor; NA¼not analysed.
aAll tumours were HER2 negative.
bLack of data for 45 cases. The bold values are statistically significant.
6C. Univariate analysis of prognostic factors
ILC N( )
Factor HR 95% CI P-value
a3b1 0.462 0.16–1.31 0.146
CD151 0.402 0.14–1.22 0.082
CD151/a3b1 0.724 0.35–1.49 0.187
CD151 /a3b1 3.125 1.09–8.99 0.034
Tumour size (T1 vs T2–4) 1.780 0.61–5.18 0.290
Grade 1.361 0.36–5.14 0.650
ER 0.372 0.08–1.72 0.206
Abbreviations: CI¼ confidence interval; ER¼oestrogen receptor; HR¼ hazards ratio; ILC¼
invasive lobular carcinoma. The bold values are statistically significant.
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with survival of patients in our ILC study population. Instead, our
results showed that the combined absence of CD151 and a3b1 was
a negative prognostic factor in patients with no lymph node
involvement. This unexpected finding gives a new insight into the
biology of ILC and possible contribution of CD151 and a3b1 to
disease progression. CD151 is highly expressed in endothelial cells
and is thought to regulate pathologic angiogenesis. It has also been
demonstrated that CD151 plays an important role in maintaining
integrity of endothelial layer (Zhang et al, 2011). Our immuno-
histochemical analysis showed that the level of CD151 expression
on endothelial cells was correlated with that seen on tumour-
associated endothelium. Although the mechanisms underlying this
‘phenotypic unity’ remains unknown, it is possible that the
compromised integrity of CD151-negative endothelium would
facilitate intravasation of CD151-negative cells. Whatever the
underlying mechanisms, the results of our study indicate that loss
of CD151-a3b1 may serve as a potential prognostic marker of poor
survival in a subgroup of patients deemed to carry a low risk of
cancer-related death (ie, lymph node negative). This could have
important clinical implications by helping to identify patients likely
to benefit from adjuvant therapy.
In summary, the results of our comparative analysis of clinical
significance of CD151/integrin a3b1 in ILC and IDC highlight
considerable differences in biology between these two BCa types.
Furthermore, the study suggests that evaluation of the level of
CD151/a3b1 expression might provide important information on
behaviour of ILC tumours and identify patients with increased risk
of distant metastases, commonly considered ineligible for routine
adjuvant therapy.
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